<p>A) median CD4+ cell count (cells/mm<sup>3</sup>) over time on ART; and, B) percentage of patients with virologic suppression (≤400 copies/mL) over time on ART.</p
<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122583#pone.0122583.g001" ...
<p><sup>†</sup>Patients with active HCV or HBV infection were excluded. Patients were on ART for a m...
BACKGROUND:: Achieving virologic suppression is a clear therapeutic goal for patients receiving comb...
<p>(A) CD4∶CD8 ratio in ART-suppressed Individuals at three timepoints (pre-ART, first timepoint on ...
#<p>, cells/µl;</p>&<p>, HIV RNA copies per ml plasma (log<sub>10</sub>);</p>*<p>, months; ART, anti...
<p>A) Virologic and immunologic failure rates over duration on ART, 95% CI; and, B) Percentage of pa...
a<p>Proportion suppressed is the proportion of patients with available data who achieved a viral loa...
<p>a. median (IQR) pVL up to 48 weeks after ART stop. b. predicted pVL over 4–48 weeks after ART sto...
<p>At each individual time points, the observed median CD4 cell counts were significantly higher in ...
<p>(A) BioRad avidity index values of 18 patients (72 samples) receiving ART with one sample before ...
1<p>Duration of viraemia was defined as (a) Patients with viral suppression on first-line ART: date ...
BACKGROUND: The SMART study randomized 5,472 human immunodeficiency virus (HIV)-infected patients wi...
<p>A) Median absolute CD4 cell count. B) Median CD4 gain 12 months after ART start.</p
Writing committee: The Antiretroviral Therapy Cohort Collaboration (ART-CC)International audienceBac...
<p>a. median (IQR) pVL up to 48 weeks after ART stop. b. predicted pVL over 4–48 weeks after ART sto...
<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122583#pone.0122583.g001" ...
<p><sup>†</sup>Patients with active HCV or HBV infection were excluded. Patients were on ART for a m...
BACKGROUND:: Achieving virologic suppression is a clear therapeutic goal for patients receiving comb...
<p>(A) CD4∶CD8 ratio in ART-suppressed Individuals at three timepoints (pre-ART, first timepoint on ...
#<p>, cells/µl;</p>&<p>, HIV RNA copies per ml plasma (log<sub>10</sub>);</p>*<p>, months; ART, anti...
<p>A) Virologic and immunologic failure rates over duration on ART, 95% CI; and, B) Percentage of pa...
a<p>Proportion suppressed is the proportion of patients with available data who achieved a viral loa...
<p>a. median (IQR) pVL up to 48 weeks after ART stop. b. predicted pVL over 4–48 weeks after ART sto...
<p>At each individual time points, the observed median CD4 cell counts were significantly higher in ...
<p>(A) BioRad avidity index values of 18 patients (72 samples) receiving ART with one sample before ...
1<p>Duration of viraemia was defined as (a) Patients with viral suppression on first-line ART: date ...
BACKGROUND: The SMART study randomized 5,472 human immunodeficiency virus (HIV)-infected patients wi...
<p>A) Median absolute CD4 cell count. B) Median CD4 gain 12 months after ART start.</p
Writing committee: The Antiretroviral Therapy Cohort Collaboration (ART-CC)International audienceBac...
<p>a. median (IQR) pVL up to 48 weeks after ART stop. b. predicted pVL over 4–48 weeks after ART sto...
<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122583#pone.0122583.g001" ...
<p><sup>†</sup>Patients with active HCV or HBV infection were excluded. Patients were on ART for a m...
BACKGROUND:: Achieving virologic suppression is a clear therapeutic goal for patients receiving comb...
DOI
Add to ORKG